Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 1;81(1):78-85.
doi: 10.1016/j.biopsych.2016.10.011. Epub 2016 Oct 19.

New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy

Nikhil M Urs  1 , Sean M Peterson  1 , Marc G Caron  2
Affiliations
Review

New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy

Nikhil M Urs et al. Biol Psychiatry. .

Abstract

The dopamine D2 receptor (D2R) is a G protein-coupled receptor that is a common target for antipsychotic drugs. Antagonism of D2R signaling in the striatum is thought to be the primary mode of action of antipsychotic drugs in alleviating psychotic symptoms. However, antipsychotic drugs are not clinically effective at reversing cortical-related symptoms, such as cognitive deficits in schizophrenia. While the exact mechanistic underpinnings of these cognitive deficits are largely unknown, deficits in cortical dopamine function likely play a contributing role. It is now recognized that similar to most G protein-coupled receptors, D2Rs signal not only through canonical G protein pathways but also through noncanonical beta-arrestin2-dependent pathways. We review the current mechanistic bases for this dual signaling mode of D2Rs and how these new concepts might be leveraged for therapeutic gain to target both cortical and striatal dysfunction in dopamine neurotransmission and hence have the potential to correct both positive and cognitive symptoms of schizophrenia.

Keywords: Antipsychotics; Arrestin; Dopamine; Functional selectivity; Schizophrenia; System bias.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Functional Selectivity at dopamine D2Rs
A) Functional selectivity at D2Rs can be regulated by the chemical structure of the ligand (shown dopamine and UNC9994) or conformations of the receptor or the complement of intracellular transducer proteins such as G proteins (Gαβγ), GPCR kinases (GRK) or β-arrestins (βarr). B) Bioluminiscence resonance energy transfer (BRET) assay for detection of βarr2 recruitment to D2Rs by dopamine (DA), aripiprazole (ARI) or UNC9994 (94A) in HEK293T cells with i) endogenous or ii) over-expression of GRK2 shows that over-expression of GRK2 renders ARI and 94A as partial agonists.
Figure 2
Figure 2. Simplified circuit schematic of the dopamine (DA) hypothesis of schizophrenia (SCZ) and implications of biased D2R signaling
As depicted in sagittal sections of a mouse brain, under normal conditions (upper panel) DA in the prefrontal cortex (PFC) through DA receptors (DARs) regulates firing of fast-spiking GABAergic parvalbumin+ interneurons (FSIs) that regulate rhythmic firing of glutamate (Glu) releasing pyramidal neurons (PYR). The PYR neurons presumably regulate neuronal activity of either striatal (STR) medium spiny neurons (MSNs), which express NMDA receptors (NMDARs) and DARs, or midbrain substantia nigra pars compacta (SN) neurons that also release DA onto striatal MSNs. In conditions that mimic schizophrenia (SCZ, middle panel), a loss of PFC DA (hypodopaminergia) or inhibition of neuronal activity of FSIs leads to over-excitability of PYRs. The enhanced activity of PYRs could presumably lead to enhanced striatal MSN activity directly or through increased DA release (hyperdopaminergia) in the striatum by SN neurons. A β-arrestin2 (βarr2) biased partial agonist like UNC9994 that acts as an agonist in the PFC but as an antagonist in the striatum could represent an ideal APD-like compound that could simultaneously reverse both hypo- and hyperdopaminergia in schizophrenia (SCZ+APD, lower panel). The proposed mechanism of such a compound would be to enhance βarr2/GRK2 but reduce Gαi activity in the PFC and inhibit βarr2/GRK2 activity in the striatum. Normal activity ( formula image), enhanced activity ( formula image) and reduced activity ( formula image).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature. 1979;277:93–96. - PubMed
    1. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiological reviews. 1998;78:189–225. - PubMed
    1. Benovic JL, Strasser RH, Caron MG, Lefkowitz RJ. Beta-adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. Proceedings of the National Academy of Sciences of the United States of America. 1986;83:2797–2801. - PMC - PubMed
    1. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ. beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science (New York, NY. 1990;248:1547–1550. - PubMed
    1. Ferguson SS, Downey WE, 3rd, Colapietro AM, Barak LS, Menard L, Caron MG. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science (New York, NY. 1996;271:363–366. - PubMed

Publication types

MeSH terms